{"schema_version":"1","generated_at":"2026-11-18T03:11:24.145Z","data_as_of":"2026-11-13","url":"https://www.findmykol.com/kol/robert-haddad","json_url":"https://www.findmykol.com/kol/robert-haddad/profile.json","record_kind":"full","profile_kind":"clinical","person":{"slug":"robert-haddad","name":"Robert Haddad","credential":"MD","title":"Chief, Division of Head and Neck Oncology","specialty":"Medical Oncology","specialty_raw":"Medical Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"Dana-Farber Cancer Institute","institution_url":"https://www.findmykol.com/institution/dana-farber-cancer-institute","city":"Boston","state":"MA","region":{"label":"Northeast","url":"https://www.findmykol.com/region/northeast"},"country":{"name":"United States","code":"US","status":"verified"}},"identifiers":{"npi":"1942259098"},"summary":"Robert Haddad is Chief, Division of Head and Neck Oncology at Dana-Farber Cancer Institute. ClinicalTrials.gov lists 15 registered studies with this person as an investigator.","overview":{"text":"Robert Haddad, MD, is Chief, Division of Head and Neck Oncology at Dana-Farber Cancer Institute. It also documents an investigator role on 15 registered clinical trials, industry payments reported by 25 companies, 1 NIH-funded awards (2019–2019).","bullets":["Top research focus: Head & Neck Cancer","15 registered trials on ClinicalTrials.gov","Open Payments reporting from 25 companies"],"generated_at":"2026-11-17"},"focus":{"indications":[{"label":"Head & Neck Cancer","therapeutic_area":"Oncology","trials":12,"topics":0,"strength":36},{"label":"Carcinoma, Squamous Cell","therapeutic_area":"Oncology","trials":6,"topics":0,"strength":18},{"label":"Carcinoma, Merkel Cell","therapeutic_area":"Oncology","trials":2,"topics":0,"strength":6},{"label":"Carcinoma, Adenoid Cystic","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Cysts","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Hypopharyngeal Neoplasms","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Melanoma","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Mucositis","therapeutic_area":"Head & Neck","trials":1,"topics":0,"strength":3},{"label":"Nasopharyngeal Neoplasms","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Papilloma","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Pharyngeal Neoplasms","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Salivary Gland Neoplasms","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Skin Neoplasms","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Xerostomia","therapeutic_area":"Head & Neck","trials":1,"topics":0,"strength":3}],"research_topics":["Head & Neck Cancer","Carcinoma, Squamous Cell","Carcinoma, Merkel Cell","Papilloma","Skin Neoplasms"],"drugs_studied":{"total":9,"shown":3,"withheld":6,"rows":[{"name":"Keytruda","generic":"Pembrolizumab","trials":0,"payments":75,"publications":0,"mentions":75},{"name":"Lenvima","generic":"Lenvatinib","trials":0,"payments":18,"publications":0,"mentions":18},{"name":"Vitrakvi","generic":"Larotrectinib","trials":0,"payments":9,"publications":0,"mentions":9}]},"works_with":{"total":29,"shown":3,"withheld":26,"rows":[{"name":"Merck Sharp & Dohme LLC","trials":0,"payments":107,"mentions":107},{"name":"Boehringer Ingelheim International GmbH","trials":0,"payments":14,"mentions":14},{"name":"Dana-Farber Cancer Institute","trials":10,"payments":0,"mentions":10}]}},"scholarship":{"note":"Research metrics are not shown for this record: either no confident publication match for this name, or more than one clinician shares the matched author record."},"trials":{"count":15,"shown":3,"withheld":12,"matched_by":"identity-adjudicated record","rows":[{"nct":"NCT06163534","title":"A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)","status":"RECRUITING","role":"Investigator","sponsor":"Tempus AI","source_url":"https://clinicaltrials.gov/study/NCT06163534","trial_url":"https://www.findmykol.com/trial/NCT06163534"},{"nct":"NCT06129864","title":"A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy","phase":"PHASE3","status":"RECRUITING","role":"Investigator","sponsor":"AstraZeneca","source_url":"https://clinicaltrials.gov/study/NCT06129864","trial_url":"https://www.findmykol.com/trial/NCT06129864"},{"nct":"NCT05280314","title":"Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors","phase":"PHASE2","status":"RECRUITING","role":"Investigator","sponsor":"IO Biotech","source_url":"https://clinicaltrials.gov/study/NCT05280314","trial_url":"https://www.findmykol.com/trial/NCT05280314"}],"source":"trials"},"payments":{"company_count":25,"program_years":{"first":2021,"last":2025},"rows_total":43,"shown":3,"withheld":40,"rows":[{"payer":"Merck Sharp & Dohme LLC","program_year":2025,"amount_usd":56080.6,"payment_count":45,"source_url":"https://openpaymentsdata.cms.gov/search?query=1942259098"},{"payer":"Exelixis Inc.","program_year":2025,"amount_usd":10119.64,"payment_count":7,"source_url":"https://openpaymentsdata.cms.gov/search?query=1942259098"},{"payer":"GlaxoSmithKline, LLC.","program_year":2025,"amount_usd":8236.75,"payment_count":7,"source_url":"https://openpaymentsdata.cms.gov/search?query=1942259098"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1942259098","source":"payments"},"prescribing":{"data_year":2024,"areas_total":1,"areas_shown":1,"areas":[{"area":"Cardiovascular","share_pct":100,"classes_total":1,"classes":[{"class":"Antiarrhythmic","setting":"prescribed","share_pct":100,"drugs":[{"name":"Lidocaine Hcl Viscous","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"facility","data_year":2024,"office_pct":0,"facility_pct":100},"source":"medicare"},"funding":{"award_count":1,"fiscal_years":{"first":2019,"last":2019},"rows_total":1,"shown":1,"withheld":0,"rows":[{"project":"U01DE029188","title":"Defining mechanisms of immunotherapy resistance in head and neck squamous cell carcinomas","fiscal_year":2019,"amount_usd":4259203,"organization":"DANA-FARBER CANCER INST","source_url":"https://reporter.nih.gov/quickSearch/U01DE029188"}],"source":"grants"},"publications":{"total":0,"shown":0,"withheld":0,"recent":[],"source":"works"},"presence":{"owned_accounts":{"total":1,"shown":1,"rows":[{"platform":"doximity","url":"https://www.doximity.com/pub/robert-haddad-md-bc5537b3","status":"verified"}]},"mentions":{"total":2,"shown":2,"rows":[{"url":"https://www.dana-farber.org/find-a-doctor/robert-i-haddad","platform":"other","status":"verified"},{"url":"https://www.hcc.harvard.edu/members/dr-robert-haddad","platform":"other","status":"verified"}]},"verified_means":"confirmed in more than one place; provisional means found and still being confirmed"},"recognition":{"education":{"total":1,"shown":1,"rows":[{"value":"MD Degree, St. Joseph University French School of Medicine in Beirut","source_url":"https://www.dana-farber.org/find-a-doctor/robert-i-haddad","status":"verified","collected_at":"2026-11-13"}]},"roles":{"total":4,"shown":3,"rows":[{"value":"Member, American Society of Clinical Oncology","source_url":"https://www.hcc.harvard.edu/members/dr-robert-haddad","status":"provisional","collected_at":"2026-11-13"},{"value":"Member, American Association for Cancer Research","source_url":"https://www.hcc.harvard.edu/members/dr-robert-haddad","status":"provisional","collected_at":"2026-11-13"},{"value":"Member, European Society of Medical Oncology","source_url":"https://www.hcc.harvard.edu/members/dr-robert-haddad","status":"provisional","collected_at":"2026-11-13"}]},"awards":{"total":3,"shown":3,"rows":[{"value":"Inducted into the Giants of Cancer Care (2026)","source_url":"https://www.hmpglobalevents.com/faculty/cpc/65601","status":"provisional","collected_at":"2026-11-13"},{"value":"2007 Partners in Excellence Award: Dysphagia Management Team for Head and Neck Cancer Patients","source_url":"https://connects.catalyst.harvard.edu/Profiles/profile/1261275","status":"provisional","collected_at":"2026-11-13"},{"value":"Giants of Cancer Care award from OncLive","source_url":"https://www.linkedin.com/posts/dana-farber-cancer-institute_please-join-us-in-congratulating-irene-ghobrial-activity-7466979783436812288-vtnp","status":"provisional","collected_at":"2026-11-13"}]},"secondary_affiliations":{"total":2,"shown":2,"rows":[{"value":"Professor of Medicine, Harvard Medical School","source_url":"https://www.hcc.harvard.edu/members/dr-robert-haddad","status":"provisional","collected_at":"2026-11-13"},{"value":"McGraw Chair in Head and Neck Oncology, Dana-Farber Cancer Institute","source_url":"https://www.hmpglobalevents.com/faculty/cpc/65601","status":"provisional","collected_at":"2026-11-13"}]},"media":{"total":2,"shown":2,"rows":[{"value":"Podcast appearance published in Targeted Oncology","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11557660/","status":"provisional","collected_at":"2026-11-13"},{"value":"Quoted in cancerhealth.com article on Keytruda immunotherapy before and after surgery for head and neck cancer","source_url":"https://www.cancerhealth.com/article/keytruda-immunotherapy-surgery-improves-outcomes-head-neck-cancer","status":"provisional","collected_at":"2026-11-13"}]}},"similar":[{"name":"Kenneth Anderson","slug":"kenneth-anderson","institution":"Dana-Farber Cancer Institute","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/kenneth-anderson","json_url":"https://www.findmykol.com/kol/kenneth-anderson/profile.json"},{"name":"Frank Hodi","slug":"frank-hodi","institution":"Dana-Farber Cancer Institute","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/frank-hodi","json_url":"https://www.findmykol.com/kol/frank-hodi/profile.json"},{"name":"Paul Richardson","slug":"paul-richardson","institution":"Dana-Farber Cancer Institute","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/paul-richardson","json_url":"https://www.findmykol.com/kol/paul-richardson/profile.json"},{"name":"Pasi Janne","slug":"pasi-janne","institution":"Dana-Farber Cancer Institute","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/pasi-janne","json_url":"https://www.findmykol.com/kol/pasi-janne/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Stuart Orkin","slug":"stuart-orkin","institution":"Harvard Medical School","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/stuart-orkin","json_url":"https://www.findmykol.com/kol/stuart-orkin/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"}],"coverage":{"note":"An identity-adjudicated profile: every section above was checked. Where a section states a count of zero, the public record was searched and nothing was found."},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"trials":12,"payments":40}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies","collected_at":"2026-11-13"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 to 2025","collected_at":"2026-11-13"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024},"grants":{"name":"NIH RePORTER","url":"https://reporter.nih.gov","provides":"Federally funded research awards, by fiscal year","collected_at":"2026-11-13"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"}},"methodology_url":"https://www.findmykol.com/about#methodology"}